First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cancer

Overview of attention for article published in ACS Pharmacology & Translational Science, June 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

So far, Altmetric has seen 8 X posts from 7 X users, with an upper bound of 25,593 followers.

RT @KFW_Lab: Having a selective inhibitor of a core catalytic subunit of complex I does not change the fact that blocking complex I is unli…

RT @KFW_Lab: Having a selective inhibitor of a core catalytic subunit of complex I does not change the fact that blocking complex I is unli…

RT @KFW_Lab: Having a selective inhibitor of a core catalytic subunit of complex I does not change the fact that blocking complex I is unli…

RT @KFW_Lab: Having a selective inhibitor of a core catalytic subunit of complex I does not change the fact that blocking complex I is unli…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.